Bladder cancer intrinsic LRFN2 drives anticancer immunotherapy resistance by attenuating CD8 + T cell infiltration and functional transition.
Anze YuJiao HuLiangmin FuGaowei HuangDingshan DengMingxiao ZhangYinghan WangGuannan ShuLanyu JingHuihuang LiXu ChenTaowei YangJinhuan WeiZhen-Hua ChenXiongbing ZuJunghang LuoPublished in: Journal for immunotherapy of cancer (2023)
Thus, LRFN2 represents a new target that can be combined with ICIs to provide a potential treatment option for BLCA.
Keyphrases